Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting

Loading news article.

Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting | WAPE

Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting

Article summary

Related companies

Comments —